Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus

This study is conducted to examine GLP-1, insulin resistance and insulin sensitivity portfolio in Malay, Chinese and Indian populations in Malaysia and to study the effect of DPPIV inhibitor in T2DM patients with different GLP-levels.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases PreDiabetes Prediabetic State

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Sultan Ismail

Johor Bahru, Johor, 81100, Malaysia

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects are newly diagnosed of T2DM according to World Health Organisation criteria) and do not receive any glucose-lowering drugs
Subjects with normal glucose tolerance test according to World Health Organisation criteria which is carried out immediately before inclusion in the study
Subjects who are willing to participate and sign the informed consent form

Exclusion criteria

Patients with pre-existing T2DM
Patients with family history of diabetes
Patients receiving glucose-lowering medications
Patients with anemia, abnormal serum creatinine level, macroalbuminuria, proliferative retinopathy, impaired liver function

Treatment and study plan

Sitagliptin

Drug

oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.

Primary outcomes

change in blood glucose load response to sitagliptin

Time frame: pre-treatment of sitagliptin and post 12-week treatment of sitagliptin

change from blood glucose response at 12 weeks
change in blood insulin response to sitagliptin

Time frame: pre-treatment of sitagliptin and post 12-week treatment of sitagliptin

change from blood insulin response at 12 weeks

Sponsors and collaborators

Lead sponsor

National University of Malaysia

Other

Registry information

Official study title

Comparative Study of Incretin System in Three Ethnic Groups With Abnormal Glucose Tolerance

Acronym: GLP-1

Important dates

Study start: 2017
Primary completion: 2019
Study completion: 2020
First posted: Sep 6, 2018
Registry last updated: Mar 15, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed